Torrent Pharmaceuticals stock (INE482A01020): Q3 profit surges 27.6% on revenue growth

Torrent Pharmaceuticals reported Q3 FY26 net profit up 27.6% to Rs 642 crore, with revenue rising 17.7% to Rs 3,251 crore. Shares gained 0.60% to Rs 4,180 on BSE.

Torrent Pharmaceuticals released strong Q3 FY26 results, posting consolidated net profit of Rs 642 crore, a 27.6% increase from the prior year, driven by 17.7% revenue growth to Rs 3,251 crore, according to Tickertape as of May 2026. Shares rose 0.60% to Rs 4,180 on the BSE following the earnings.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Torrent Pharmaceuticals Ltd
• Sector/industry: Health Care / Pharmaceuticals
• Headquarters/country: India
• Core markets: India, US, emerging markets
• Key revenue drivers: Branded generics, gastrointestinal, pain management
• Home exchange/listing venue: NSE/BSE (TORNTPHARM)
• Trading currency: INR

Torrent Pharmaceuticals: core business model

Torrent Pharmaceuticals manufactures and markets branded and generic pharmaceutical products, focusing on therapeutic areas like gastrointestinal, pain management, and anti-infectives. The company operates primarily in India but has a growing presence in the US and other international markets through subsidiaries like Vista Pharmaceuticals, its largest domestic division, according to Moneycontrol.

With a market cap of approximately ?1,52,879 crore, Torrent ranks among India's top pharma firms. Its business model emphasizes affordable generics and branded formulations for common ailments, contributing to steady domestic sales growth.

Main revenue and product drivers for Torrent Pharmaceuticals

Revenue is driven by domestic sales from Vista Pharmaceuticals, which handles key areas like GI and pain relief, alongside international generics. Q3 FY26 results showed robust 17.7% top-line growth to Rs 3,251 crore for the period ended December 2025, published in early 2026 per Tickertape as of May 2026.

Profit margins expanded, lifting net profit 27.6% to Rs 642 crore in Q3 FY26 versus Q3 FY25. The stock traded at around Rs 4,180-4,483 on BSE/NSE recently, with a P/E ratio near 80, reflecting high growth expectations.

Industry trends and competitive position

India's pharma sector benefits from US generics demand and domestic branded drug sales. Torrent's focus on high-volume therapeutics positions it well amid rising healthcare needs in emerging markets. Recent stock performance shows a 39.52% yearly gain as of early 2026, per Investing.com historical data.

Why Torrent Pharmaceuticals matters for US investors

Torrent Pharmaceuticals offers US investors exposure to India's booming generics market, with ambitions in the US via ANDA filings like the Novartis case on heart drugs. Its US-facing operations provide a play on global pharma outsourcing trends relevant to American healthcare costs.

Conclusion

Torrent Pharmaceuticals demonstrated solid Q3 FY26 performance with profit and revenue growth, supporting recent share price gains. The company's domestic strength and international push, including US market efforts, underline its role in global pharma. Investors track ongoing developments like merger progress with JB Chemicals for future scale.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.